The future of the type 1 diabetes field

[Northerner]

We had a wide-ranging interview with two of the pioneers of the Helmsley Charitable Trust’s (HCT) Type 1 Diabetes (T1D) program (which gives $50 million a year to type 1 research, treatment, and services): HCT trustee David Panzirer, and patient advocate Dana Ball. In part two of our interview, David and Dana share incredible insights on what they view as the biggest challenges and promises in the type 1 diabetes field. What do they think is the most important advance? How would they define a cure? And what type 2 drugs can be used for type 1? Read on for more and stay tuned for further installments in our five-part series:

http://www.diatribe.org/issues/64/diatribe-dialogue

 

[heasandford]

Part 3 is in this months Diatribe, out now - http://diatribe.org/issues/65/diatribe-dialogue